Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481R BTK L528W |
| Therapy | NX-2127 |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481R BTK L528W | chronic lymphocytic leukemia | predicted - sensitive | NX-2127 | Case Reports/Case Series | Actionable | In a Phase I trial, NX-2127 treatment resulted in a partial response in a patient with chronic lymphocytic leukemia harboring BTK C481R and L528W, who had progressed on prior BTK inhibitors (PMID: 38301010; NCT04830137). | 38301010 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38301010) | Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. | Full reference... |